US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

24.99

+0.12000.48%

Post-market: 24.990.00000.00%16:31 EDT

Volume:326.15K

Turnover:8.07M

Market Cap:1.15B

PE:-9.97

High:25.31

Open:24.52

Low:24.25

Close:24.87

52wk High:42.27

52wk Low:6.43

Shares:46.11M

Float Shares:14.96M

Volume Ratio:0.72

T/O Rate:2.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5062

EPS(LYR):-3.7760

ROE:-29.42%

ROA:-20.14%

PB:4.37

PE(LYR):-6.62

Loading ...

Overview Company News Filings

Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares

Citizens JMP Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

CEO Abraham Ceesay Reports Disposal of Common Shares in Rapport Therapeutics Inc

Rapport Therapeutics Initiated at Buy by Truist Securities

Truist Initiates Rapport Therapeutics at Buy With $44 Price Target

MT Newswires Live

Rapport Therapeutics director buys $1.03M in common stock

Director Reid M. Huber Reports Acquisition of Common Shares in Rapport Therapeutics Inc

Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics assigned Buy rating at Goldman Sachs

Director’s Bold Move: Major Stock Purchase at Rapport Therapeutics!

Director Wendy B. Young Reports Acquisition of Common Shares in Rapport Therapeutics Inc

Rapport Therapeutics Inc. to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

U.S. RESEARCH ROUNDUP-Chewy, Phillips 66, Vimeo

Rapport Therapeutics Announces Public Offering Agreement

Rapport Therapeutics Inc. Announces $234.7M Public Offering to Fund Clinical Trials

Cheryl Gault, COO of Rapport Therapeutics Inc., Reports Disposal of Common Shares

Biotech Company Rapport Plunges 18.8% Following Completion of $250 Million Public Offering

BUZZ-Rapport Therapeutics slips after $250 mln equity raise

BRIEF-Rapport Says Public Offering Of 9.6 Million Shares Of Its Common Stock At A Price Of $26.00 Per Share

Rapport Therapeutics Inc - Prices Public Offering at $26.00 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":24.99,"timestamp":1760731200000,"preClose":24.87,"halted":0,"volume":326152,"hourTrading":{"tag":"盘后","latestPrice":24.99,"preClose":24.99,"latestTime":"16:31 EDT","volume":4577,"amount":114379.23,"timestamp":1760733118536},"delay":0,"floatShares":14959986,"shares":46113305,"eps":-2.506155,"marketStatus":"Market Closed","change":0.12,"latestTime":"10-17 16:00:00 EDT","open":24.52,"high":25.31,"low":24.25,"amount":8073514.42368,"amplitude":0.042622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.506155,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":24.87,"postHourTrading":{"tag":"盘后","latestPrice":24.99,"preClose":24.99,"latestTime":"16:31 EDT","volume":4577,"amount":114379.23,"timestamp":1760733118536},"volumeRatio":0.7203343975727433,"impliedVol":0.8226,"impliedVolPercentile":0.4469},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14959986,"roa":"-20.14%","roe":"-29.42%","lyrEps":-3.775953,"volumeRatio":0.7203343975727433,"shares":46113305,"dividePrice":0,"high":25.31,"amplitude":0.042622,"preClose":24.87,"low":24.25,"week52Low":6.43,"pbRate":"4.37","week52High":42.2685,"institutionHeld":0,"latestPrice":24.99,"eps":-2.506155,"divideRate":0,"volume":326152,"delay":0,"ttmEps":-2.506155,"open":24.52,"prevYearClose":17.74,"prevWeekClose":26.5,"prevMonthClose":29.7,"prevQuarterClose":29.7,"fiveDayClose":26.5,"twentyDayClose":26.36,"sixtyDayClose":16.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1758168000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-10-16","current":-9.97145,"percent":0.233918,"low":-19.654107,"twenty":-13.865457,"median":-9.199351,"eighty":-5.252778,"high":-3.640031,"avg":-9.609614,"sd":4.1794,"marketCap":1188794738},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-16","current":-13.461305,"twenty":-13.865457,"median":-9.199351,"eighty":-5.252778,"marketCap":1188794738}],"updateTime":1760770677744},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576777343","title":"Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576777343","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576777343?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:30","pubTimestamp":1760646643,"startTime":"0","endTime":"0","summary":"Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL3yb6GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2569725089","title":"Citizens JMP Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569725089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569725089?lang=en_us&edition=fundamental","pubTime":"2025-09-24 10:05","pubTimestamp":1758679510,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason Butler from Citizens JMP reiterated a Buy rating on Rapport Therapeutics, Inc., with a price target of $77.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citizens-jmp-sticks-to-their-buy-rating-for-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citizens-jmp-sticks-to-their-buy-rating-for-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","JMP"],"gpt_icon":0},{"id":"2569712877","title":"CEO Abraham Ceesay Reports Disposal of Common Shares in Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712877","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712877?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:25","pubTimestamp":1758644733,"startTime":"0","endTime":"0","summary":"Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL67x2x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2567486066","title":"Rapport Therapeutics Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2567486066","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567486066?lang=en_us&edition=fundamental","pubTime":"2025-09-16 22:50","pubTimestamp":1758034200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 16, 2025 10:50 ET (14:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2567507109","title":"Truist Initiates Rapport Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2567507109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567507109?lang=en_us&edition=fundamental","pubTime":"2025-09-16 18:38","pubTimestamp":1758019093,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAPP"],"gpt_icon":0},{"id":"2567128997","title":"Rapport Therapeutics director buys $1.03M in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2567128997","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567128997?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:40","pubTimestamp":1757972412,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Rapport Therapeutics (RAPP) disclosed that its director Steven Paul bought 41.7K shares of common stock on September 12th i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-director-buys-1-03m-in-common-stock-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-director-buys-1-03m-in-common-stock-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RAPP","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2567714244","title":"Director Reid M. Huber Reports Acquisition of Common Shares in Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2567714244","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567714244?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:05","pubTimestamp":1757966748,"startTime":"0","endTime":"0","summary":"Reid M. Huber, a Director at Rapport Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL4yP16q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Reid M. Huber Reports Acquisition of Common Shares in Rapport Therapeutics Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2566920304","title":"Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566920304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566920304?lang=en_us&edition=fundamental","pubTime":"2025-09-12 17:30","pubTimestamp":1757669419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Rubrik, Inc. Class A (RBRK – Research Report) and Rapport Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-rubrik-inc-class-a-rbrk-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-rubrik-inc-class-a-rbrk-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RBRK","BK4141","RAPP","BK4613","BK4007","NA","BK4097","BK4112","LU2286300806.USD"],"gpt_icon":0},{"id":"2566920518","title":"Rapport Therapeutics assigned Buy rating at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2566920518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566920518?lang=en_us&edition=fundamental","pubTime":"2025-09-12 17:25","pubTimestamp":1757669115,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics (RAPP) with a Buy rating and $51 price target from its Early-Stage Biotech desi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assigned-buy-rating-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assigned-buy-rating-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2566949081","title":"Director’s Bold Move: Major Stock Purchase at Rapport Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2566949081","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566949081?lang=en_us&edition=fundamental","pubTime":"2025-09-12 10:12","pubTimestamp":1757643139,"startTime":"0","endTime":"0","summary":"New insider activity at Rapport Therapeutics, Inc. ( ($RAPP) ) has taken place on September 11, 2025. Director Wendy B. Young has made a significan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/directors-bold-move-major-stock-purchase-at-rapport-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/directors-bold-move-major-stock-purchase-at-rapport-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","RAPP","BK4139","BK4007"],"gpt_icon":0},{"id":"2566126499","title":"Director Wendy B. Young Reports Acquisition of Common Shares in Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2566126499","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566126499?lang=en_us&edition=fundamental","pubTime":"2025-09-12 06:14","pubTimestamp":1757628868,"startTime":"0","endTime":"0","summary":"Wendy B. Young, a Director at Rapport Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL8xcSSb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Wendy B. Young Reports Acquisition of Common Shares in Rapport Therapeutics Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566195879","title":"Rapport Therapeutics Inc. to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2566195879","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566195879?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:05","pubTimestamp":1757621132,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing precision medicines for neurological and psychiatric disorders, will participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. The virtual event will feature a fireside chat with Rapport's management on Wednesday, September 17, 2025, at 11:20 am ET. Interested parties can access the live and archived webcast of the chat via the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL1nd2j0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","RAPP"],"gpt_icon":0},{"id":"2566527549","title":"U.S. RESEARCH ROUNDUP-Chewy, Phillips 66, Vimeo","url":"https://stock-news.laohu8.com/highlight/detail?id=2566527549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566527549?lang=en_us&edition=fundamental","pubTime":"2025-09-11 15:57","pubTimestamp":1757577456,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Chewy, Phillips 66, Vimeo Sept 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chewy, Phillips ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3N3UY0HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHWY","PBF","PSX","LU0266512127.USD","RAPP","NEUP","DINO","LU0368265418.SGD","TPR","DK","IE00B3CCJ963.GBP","BK4200","LU1559883803.SGD","LU1941712264.USD","CASY","IE0009354923.USD","LU0208291251.USD","VMEO","BK4023","MNSH","BK4585","IE00B2Q91V27.USD","LU1169590202.USD","MPC","LU1169589451.USD","IE00BGHQF524.EUR","LU1941712348.USD","IE00B3T34201.USD","BK4138","BK4221","LU0130102774.USD","BK4113","WK","FROG","RBRK","BK4139","WY","LU0980610538.SGD","PARR","BK4202","VLO","LU0130517989.USD","BK4084","LU0345780950.USD","LU0566484027.USD","LU0757428866.USD","LU1267930227.SGD","CAMP","LU0310800965.SGD"],"gpt_icon":0},{"id":"2566762980","title":"Rapport Therapeutics Announces Public Offering Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2566762980","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566762980?lang=en_us&edition=fundamental","pubTime":"2025-09-11 05:51","pubTimestamp":1757541076,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) just unveiled an update. On September 9, 2025, Rapport Therapeutics, Inc. entered into an underwriting agree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-announces-public-offering-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-announces-public-offering-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139","RAPP"],"gpt_icon":0},{"id":"2566980846","title":"Rapport Therapeutics Inc. Announces $234.7M Public Offering to Fund Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2566980846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566980846?lang=en_us&edition=fundamental","pubTime":"2025-09-11 05:23","pubTimestamp":1757539395,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. has entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities  LLC, and Stifel, Nicolaus & Company, Incorporated for a public offering of 9,615,385 shares of its common stock. Priced at $26.00 per share, the offering is expected to generate approximately $234.7 million in net proceeds, excluding potential additional shares the underwriters may purchase. The funds will be used to support ongoing and planned clinical trials, research and development initiatives, and general corporate purposes. The offering is anticipated to close around September 11, 2025, pending customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. publis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL44RL3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","IE0004086264.USD","LU2237443622.USD","LU0251142724.SGD","BK4552","LU2471134952.CNY","RAPP","LU2237443549.SGD","LU1894683264.USD","BK4533","IE0002270589.USD","LU0061475181.USD","LU0742534661.SGD","BK4585","LU1804176565.USD","LU2237438978.USD","LU2471134523.USD","IE0034235188.USD","BK4550","LU2265009873.SGD","LU0048573561.USD","IE00B19Z3B42.SGD","LU0106831901.USD","BK4504","LU1868836757.USD","LU2237443895.HKD","IE00B19Z3581.USD","LU2471134796.USD","LU0251131958.USD","SF","LU2237443978.SGD","LU2750360641.GBP","IE00BFXG1179.USD","LU1868837136.USD","BK4559","LU2471134879.HKD","IE00BSNM7G36.USD","LU1791807156.HKD","LU2750360997.AUD","LU1668664300.SGD","LU2237443382.USD","LU1868837300.USD","JEF","LU1894683348.USD","LU1868836591.USD","BK4516","BK4007","IE0004091025.USD","BK4127","BK4588"],"gpt_icon":0},{"id":"2566079984","title":"Cheryl Gault, COO of Rapport Therapeutics Inc., Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2566079984","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566079984?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:15","pubTimestamp":1757535342,"startTime":"0","endTime":"0","summary":"Cheryl Gault, Chief Operating Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL59yCgy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"1117546794","title":"Biotech Company Rapport Plunges 18.8% Following Completion of $250 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1117546794","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117546794?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:00","pubTimestamp":1757516459,"startTime":"0","endTime":"0","summary":"In early Wednesday trading, Rapport Therapeutics, Inc. (RAPP), a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases, saw its stock price...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","CNS","BK4135","BK4007"],"gpt_icon":0},{"id":"2566167722","title":"BUZZ-Rapport Therapeutics slips after $250 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2566167722","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566167722?lang=en_us&edition=fundamental","pubTime":"2025-09-10 18:28","pubTimestamp":1757500137,"startTime":"0","endTime":"0","summary":"** Rapport Therapeutics' RAPP.O shares down 2.5% to $27.34 before the bell after follow-on offering priced. ** Co late Tues announced ~9.6 mln shares at $26 for $250 mln gross proceeds. ** Offering price represents 7.2% discount to stock's last close. RAPP shares on Mon soared ~119% to close at $31.47 after its seizure drug, RAP-219, met mid-stage trial goals. ** Its shares fell nearly 11% on Tues after co commenced the offering. to primarily fund ongoing and planned clinical trials advancing RAP-219, other R&D and for working capital and other purposes, per the prospectus filing. ** Goldman Sachs, Jefferies, TD Cowen and Stifel are joint bookrunners for the offering. ** Boston-headquartered Rapport has ~36.5 mln shares outstanding for ~$1 bln current market cap. ** Rapport, backed by Johnson & Johnson JNJ.N, went public in Jun 2024 after IPO priced at $17. ** All 6 analysts are bullish on RAPP; median PT of $50 up from $35 a month ago, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL6N3UX0IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0289739699.SGD","IE00B19Z3581.USD","JNJ","LU1868836591.USD","LU2237443622.USD","IE00B3PB1722.GBP","LU1674673428.USD","BK4592","LU0122379950.USD","RAPP","LU0640476718.USD","IE00BLSP4239.USD","LU0106831901.USD","LU0912757837.SGD","LU2112291526.USD","LU1032955483.USD","IE0034235303.USD","LU1929549753.HKD","SF","LU0320765646.SGD","LU2237443978.SGD","IE00BJT1NW94.SGD","IE00BVYPNW00.USD","LU2237443549.SGD","LU1066053197.SGD","LU0203347892.USD","LU2237438978.USD","LU1506573853.SGD","IE0009355771.USD","LU1732799900.SGD","LU0985320562.USD","LU1668664300.SGD","IE00B1BXHZ80.USD","SG9999001440.SGD","LU1221951046.USD","LU1057294990.SGD","LU1244550577.SGD","LU2471134952.CNY","LU2592432038.USD","LU1430594728.SGD","LU0234572021.USD","LU1804176565.USD","IE0004091025.USD","LU1066051498.USD","LU2129689605.HKD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","BK4504","LU0345769128.USD"],"gpt_icon":0},{"id":"2566640111","title":"BRIEF-Rapport Says Public Offering Of 9.6 Million Shares Of Its Common Stock At A Price Of $26.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2566640111","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566640111?lang=en_us&edition=fundamental","pubTime":"2025-09-10 09:20","pubTimestamp":1757467251,"startTime":"0","endTime":"0","summary":"BRIEF-Rapport Says Public Offering Of 9.6 Million Shares Of Its Common Stock At A Price Of $26.00 Per ShareSept 9 (Reuters) - Rapport Therapeutics Inc RAPP.O:RAPPORT ANNOUNCES PRICING OF PUBLIC OFFERI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA2Z7QRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2566640608","title":"Rapport Therapeutics Inc - Prices Public Offering at $26.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2566640608","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566640608?lang=en_us&edition=fundamental","pubTime":"2025-09-10 09:17","pubTimestamp":1757467038,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA2Z7QRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}